{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:05:51Z","timestamp":1792425951778,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Mirvetuximab soravtansine (MIRV) is an antibody\u2010drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor \u03b1 (FR\u03b1)\u2010targeting antibody via the cleavable sulfo\u2010SPDB linker. MIRV targets and binds to FR\u03b1 with high affinity and specificity, releasing the DM4 payload intracellularly following MIRV\u2010FR\u03b1 complex internalization and degradation. DM4 and its metabolite S\u2010methyl\u2010DM4 suppress microtubule dynamic instability, which triggers cell cycle arrest and apoptosis. Selective FR\u03b1\u2010overexpression in \u2265\u200990% of epithelial ovarian tumor cells and its ability to internalize large molecules make it a highly attractive ADC target for epithelial ovarian cancers (including primary peritoneal and fallopian tube cancers). Although up to 80% of patients initially respond to platinum\u2010based therapies, the majority of tumors will recur and become platinum\u2010resistant. Unfortunately, platinum\u2010resistant ovarian cancer (PROC) carries a poor prognosis with an overall survival of 12\u201314\u2009months from the time of platinum\u2010resistance, and prior to MIRV approval in 2022, little had changed in treatment options for decades. The MIRV Phase 3 registrational trial (MIRASOL) showed superiority of MIRV vs. chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients with high (\u2265\u200975%) FR\u03b1\u2010expression PROC, showing an objective response rate of 42% versus 16%, a median progression\u2010free survival of 5.6 versus 4.0\u2009months, and an overall survival of 16.5 versus 12.8\u2009months. Here, we briefly review MIRV mechanism of action, pharmacokinetics, pharmacodynamics, and key clinical efficacy and safety data.<\/jats:p>","DOI":"10.1111\/cts.70447","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:00:38Z","timestamp":1768550438000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-0449","authenticated-orcid":false,"given":"Rajeev","family":"Menon","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1239-170X","authenticated-orcid":false,"given":"Emarjola","family":"Bako","sequence":"additional","affiliation":[{"name":"Pharmacovigilance and Patient Safety AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-4843","authenticated-orcid":false,"given":"Shuhan","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-3720","authenticated-orcid":false,"given":"James","family":"Stec","sequence":"additional","affiliation":[{"name":"Medical Affairs AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7063-3911","authenticated-orcid":false,"given":"Sheetal","family":"Thakur","sequence":"additional","affiliation":[{"name":"Regulatory Affairs Oncology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-2299","authenticated-orcid":false,"given":"Emily","family":"Deutschman","sequence":"additional","affiliation":[{"name":"Precision Medicine Oncology AbbVie Inc.  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-3231","authenticated-orcid":false,"given":"Olga","family":"Ab","sequence":"additional","affiliation":[{"name":"Precision Medicine Oncology AbbVie Inc.  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7923-0180","authenticated-orcid":false,"given":"Shweta","family":"Jain","sequence":"additional","affiliation":[{"name":"Clinical Development Oncology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"National Institutes of Health: National Cancer Institute: Surveillance Epidemiology and End Results Program \u201cCancer Stat Facts: Ovarian Cancer \u201d (2024) https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.04.017"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S366681"},{"key":"e_1_2_13_7_1","first-page":"45","article-title":"Update on First\u2010Line Treatment of Advanced Ovarian Carcinoma","volume":"5","author":"Kemp Z.","year":"2013","journal-title":"International Journal of Women's Health"},{"key":"e_1_2_13_8_1","volume-title":"ELAHERE (mirvetuximab soravtansine\u2010gynx) [Package Insert]","year":"2025"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_2_13_11_1","unstructured":"European Medicines Agency \u201cELAHERE (Mirvetuximab Soravtansine\u2010gynx) Summary of Product Characteristics. EU\/1\/24\/1866 \u201d (2024) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/elahere\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_13_12_1","unstructured":"Swissmedic Elahere (Active Substance: Mirvetuximab Soravtansine): Summary Report on Authorisation Dated 10 June 2025 https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/about\u2010us\/publications\/public\u2010summary\u2010swiss\u2010par\/public\u2010summary\u2010swiss\u2010par\u2010elahere.html."},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0991"},{"key":"e_1_2_13_14_1","volume-title":"VENTANA FOLR1 (FOLR1\u20102.1) RxDx Assay [Package Insert]","year":"2022"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21712"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.06.008"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252211927"},{"key":"e_1_2_13_18_1","first-page":"3567","article-title":"Alpha\u2010Folate Receptor Expression in Epithelial Ovarian Carcinoma and Non\u2010Neoplastic Ovarian Tissue","volume":"28","author":"Markert S.","year":"2008","journal-title":"Anticancer Research"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15937"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0930"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082160"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201014\u20101095"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4489"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0644"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30736"},{"key":"e_1_2_13_27_1","unstructured":"European Medicines Agency Assessment Report: Elahere. EMA\/473768\/2024 https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/elahere\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00874-2"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16250"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005401"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00021-X"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.011"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105205"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.013"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"e_1_2_13_38_1","unstructured":"National Comprehensive Cancer Network \u201cNCCN Guidelines: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer (Version 1.2025) \u201d (2025) https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1453."},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.12.017"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(21)00771-X"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5504"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2372241"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.017"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.01.045"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT008"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:07:59Z","timestamp":1785776879000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/cts.70447"],"URL":"https:\/\/doi.org\/10.1111\/cts.70447","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70447"}}